-

BostonGene Chief Medical Officer to Discuss Biologically Grounded AI and Multimodal Data in Oncology Drug Development at the 2nd Annual Global Cancer Research & Innovation Symposium

Nathan Fowler, MD, will join oncology and biotechnology leaders to discuss how integrated molecular and immune data can improve clinical-development decisions

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that Nathan Fowler, MD, Chief Medical Officer, will participate in the 2nd Annual Global Cancer Research & Innovation Symposium, taking place October 5–6, 2026, in New York City. Dr. Fowler will join leaders from across the oncology ecosystem for a discussion on how multimodal data can be integrated to improve drug discovery and clinical development.

By placing each patient and drug into a broader biological context, we can identify mechanisms of response and resistance, define the patients most likely to benefit...

Share

As oncology therapies become more precise, development teams increasingly need to understand how genomic alterations, tumor states, and immune biology interact within individual patients. The panel, titled "Multi-Omics: One Size Does Not Fit All!," will examine how whole genome sequencing, single-cell analysis, spatial transcriptomics, and other advanced modalities can be combined to explain therapeutic response and resistance, identify biologically defined patient populations, and guide trial design and therapeutic strategy.

“The objective is not simply to generate more data. It is to understand why a therapy works in one patient and not another, and then translate that biology into decisions that improve clinical development,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “By placing each patient and drug into a broader biological context, we can identify mechanisms of response and resistance, define the patients most likely to benefit, and help development teams make better decisions about biomarkers, trial design, and therapeutic strategy. I look forward to discussing how these capabilities can help move precision oncology from biological insight to clinical action.”

Session Details:

  • Title: Multi-Omics: One Size Does Not Fit All!
  • Moderator:
    • Stan Skrzypczak, MS, MBA, Managing Partner, 5 Prime Life Science Consulting
  • Featured Panelists:
    • Nathan Fowler, MD, Chief Medical Officer, BostonGene
    • Serge Saxonov, PhD, CEO and Co-Founder, 10x Genomics
    • Elli Papaemmanuil, PhD, Global Vice President, Oncology, Translational Medicine, Genentech
    • Prathesh Sathyan, PhD, Head of AMR Oncology and Medical Affairs, Illumina

For more information on the conference or to view the full agenda, visit avbcc.org/gcris.

About BostonGene Corporation

BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.

Contacts

BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@BostonGene.com

BostonGene Corporation


Release Versions

Contacts

BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@BostonGene.com

Social Media Profiles
More News From BostonGene Corporation

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom